COMPARISON OF SILODOSIN AND TAMSULOSIN IN MEDICAL EXPULSIVE THERAPY OF DISTAL URETERIC CALCULI

NCT ID: NCT05790902

Last Updated: 2023-03-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

142 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-01

Study Completion Date

2023-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

to compare efficacy and safety of Silodosin and Tamsulosin in Medical expulsive therapy of Distal Ureteric Calculi.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

to compare efficacy and safety of Silodosin and Tamsulosin in Medical expulsive therapy of Distal Ureteric Calculi in our local setup to find out the optimal drug which promptly and quickly cures the disease thus enabling the person to return to routine activity with less adverse effects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Silodosin, Tamsulosin, Medical Expulsive Therapy, Distal Ureteric Calculi

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Silodosin Group

The patients used Silodosin for ureteric calculi

Group Type EXPERIMENTAL

Silodosin

Intervention Type DRUG

The patients used Silodosin for Medical expulsive therapy of ureteric calculi

Tamsulosin Group

The patients used Tamsulosin for ureteric calculi

Group Type EXPERIMENTAL

Tamsulosin

Intervention Type DRUG

The patients used Tamsulosin for Medical expulsive therapy of ureteric calculi

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Silodosin

The patients used Silodosin for Medical expulsive therapy of ureteric calculi

Intervention Type DRUG

Tamsulosin

The patients used Tamsulosin for Medical expulsive therapy of ureteric calculi

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* symptomatic, unilateral, single, uncomplicated Distal Ureteric Calculi of \<10 mm in size (on plain CT KUB)

Exclusion Criteria

* solitary kidney, bilateral ureteric stones, UTI, renal impairment, high-grade hydronephrosis (Grades 3 and 4), any history of previous endoscopic or surgical interventions, pregnancy, diabetes mellitus,
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Armed Forces Institute of Urology, Rawalpindi

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

AJ Arif

DR ABDUL JABBAR ARIF

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

AFIU Rawalpindi

Rawalpindi, Punjab Province, Pakistan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Pakistan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AFIU-2022-02

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Silodosin vs Tamsulosin as MET
NCT05570084 UNKNOWN PHASE3
Silodosin in Management of Lower Ureteral Stones
NCT06381206 COMPLETED PHASE1/PHASE2